Back to news

BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

PR Newswire•18/11/2026•09:00 ET
0

Key Highlights

  • ➤BioLineRx (BLRX) will release Q3 2026 results November 23 before U.S. markets open
  • ➤Management will host an 8:30 a.m. EST conference call featuring CEO Philip Serlin
  • ➤GLIX1 Phase 1/2a trial initiated in Q1 2026 for glioblastoma and solid tumors
  • ➤APHEXDA is commercialized globally outside Asia by Ayrmid and in Asia by Gloria Biosciences
  • ➤Phase 2b PDAC trial for motixafortide remains ongoing under Columbia University collaboration

BioLineRx to Report Third Quarter 2026 Results on November 23, 2026 PR Newswire

TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2026 on Monday, November 23, 2026, before the U.S. markets open.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in